AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03531255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegcetacoplan
Description: Complement (C3) Inhibitor
Study NCT01321411 — intervention group
Intervention type: OTHER
Intervention: Near Infrared Spectroscopy
Description: Healthy Volunteers:~Study #1 (Abnormal Pulmonary Resistance) subjects will breathe through a Starling resistor simulating abnormal pulmonary resistance. WOB and RMBF will be measured during resting breathing, as well as at 25%, 50% and 75% of MVV.~Study #2 (Abnormal Pulmonary Compliance) subjects will breathe while wearing a chest binder simulating abnormal pulmonary resistance. WOB and RMBF will be measured during resting breathing, as well as at 25%, 50% and 75% of MVV.
Study NCT01321411 — intervention group
Intervention type: OTHER
Intervention: Near Infrared Spectroscopy
Description: Clinical Volunteers:~Study #3 (Abnormal Pulmonary Resistance) subjects recovering from COPD exacerbations will breathe through their ventilator circuit. PAV support will be altered to change the subjects' WOB. WOB and RMBF will be measured during resting breathing, as well as at 75%, 125% and 150% of baseline WOB.~Study #4 (Abnormal Pulmonary Compliance) subjects recovering from ARDS will breathe through their ventilator circuit. PAV support will be altered to change the subjects' WOB. WOB and RMBF will be measured during resting breathing, as well as at 75%, 125% and 150% of baseline WOB.
Study NCT01010464 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adhesion Reduction Plan
Description: Lysis of adhesions and application of a minimum of 4 sheets of a sodium hyaluronate-based bioresorbable membrane
Study NCT02988908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Participants received donepezil as 5mg pills per day for 6 weeks, then 10 mg per day for the remainder of the 52-week trial.~Participants also received 2 weeks of memory training at weeks 13-14
Study NCT02988908 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Participants received placebo as 5mg pills per day for 6 weeks, then 10 mg per day for the remainder of the 52-week trial.~Participants also received 2 weeks of memory training at weeks 13-14
Study NCT03985202 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured exercise programme
Description: 9 week structured exercise programme. 3 sessions per week. (Intervention).The patient will be invited to the hospital for a 45-minute exercise counselling session, incorporating behaviour modification techniques. These behaviour modification techniques will be reinforced during the supervised exercise sessions. Participants will be offered 3 sessions of supervised aerobic interval exercise sessions per week on a cycle ergometer for 9 weeks.Exercise programmes will be tailored to each patient, taking previous level of activity, mobility and any barriers to exercise into consideration.
Study NCT04035291 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: exercises,play therapy models and positioning, handling and holding principles for babies, daily routins
Study NCT04035291 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: exercises,play therapy models and positioning, handling and holding principles for babies, daily routins
Study NCT02847312 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High avenanthramide, phenolic acid
Description: High avenanthramide and high phenolic acid, matched with energy and insoluable fibre.
Study NCT02847312 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low avenanthramide, medium phenolic acid
Description: Low avenanthramide and moderate phenolic acid, matched with energy and insoluable fibre.
Study NCT02847312 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Control are matched with energy and insoluable fibre.
Study NCT02353988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: Patients in experimental group are designated to take bicalutamide orally, 150mg on a continuous schedule. The investigator should pay attention to the patients' adverse event. Every month, the patients will be evaluated for the adverse event by the criterion National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 3.0. Every 2 months, the patients will be evaluated for the clinical effects. If disease progressed, the patients would be ruled out.~Treatment continued until disease progression, unacceptable toxic effects, patient or physician request to discontinue, or serious protocol non-compliance. A maximum of 2 dose reductions for grade >= 3 toxicity were allowed (100 and 50 mg). A maximum of 2 weeks was permitted for treatment delays due to toxicity.
Study NCT02353988 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physician's Choice
Description: The comparator group, treatment of physician's choice (TPC), represented a mix of agents (both approved and non-approved for metastatic breast cancer) to mirror clinical practice at the time in this setting.~The 60 patients are enrolled in the study, before randomized to the two arms, each of them will be assessed for eligibility and then their proposed TPC.~Treatment continued until disease progression, unacceptable toxic effects, patient or physician request to discontinue, or serious protocol non-compliance.
Study NCT02302300 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Manufacturer STELLAR 150
Description: 5 days of non-invasive ventilation at two levels of pressure from it pre-operative, followed by 5 days in post-operative.
Study NCT03123172 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: arterial and central venous blood gases
Description: withdrawal of arterial and central venous blood gases to measure Co2 gap
Study NCT02667808 — intervention group
Intervention type: OTHER
Intervention: Focus Group
Description: Subjects will participate in four to eight group discussions aimed to evaluate fertility intentions, family planning, and sexual health behaviors. Discussions will be 1-2 hours in length. Groups will be conducted among men and women.
Study NCT02667808 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Participants will complete a questionnaire assessing reproductive health knowledge, attitudes and practices related to family planning, and fertility and sexual health. The questionnaire will take no longer than 30 minutes to complete.
Study NCT04390958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: 125mg/m2 ivgtt d1、d8
Study NCT04390958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 60mg/m2 ivgtt d1 or d1-2
Study NCT04390958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1750mg/m2 po bid d1-14
Study NCT02061930 — intervention group
Intervention type: PROCEDURE
Intervention: single crowns supported by implants
Description: The implant placement procedures were planned based on clinical and radiographic evaluation. During the surgeries, the mid-crestal incision and intra-crevicular incision were made following local articaine infiltration anesthesia. No releasing incisions were made. After full-thickness flaps were elevated labially and lingually to expose the alveolar ridge, the implants were placed according to the standard surgical procedures defined by the manufacturer. After a healing time of 10-16 weeks, implant-level impressions were taken. The porcelain (Ivoclar-Vivadent AG, Schaan, Lichtenstein) fused to noble metal crowns were fabricated. Abutment screws were torqued to 15 Ncm. Crowns were cemented with HY-bond Glassionomer Cement
Study NCT04466904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI362
Description: Administrated by subcutaneous injection
Study NCT04466904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administrated by subcutaneous injection
Study NCT04466904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Description: Administrated by subcutaneous injection
Study NCT03160781 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma
Description: Combination of Intraosseous and Intraarticular Infiltration of Platelet Rich Plasma
Study NCT02346006 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: More physical activity.
Description: Subjects receiving more physical activity in school.
Study NCT02950948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Progesterone will be administered subcutaneously once a day for 14 days/month, for 12 months.
Study NCT02950948 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo solution will be administered subcutaneously once a day for 14 days/month, for 12 months.
Study NCT02441036 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultherapy Treatment
Description: Focused ultrasound energy delivered below the surface of the skin.
Study NCT01948999 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ECT
Description: Electroconvulsive Therapy inclusive anesthesia and concomitant muscular paralysis
Study NCT01948999 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: SHAM ECT
Description: Anesthesia and concomitant muscular paralysis
Study NCT01948999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anesthesia
Description: Temporary induced state of analgesia
Study NCT01948999 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Anesthesia
Description: Temporary induced state of analgesia
Study NCT04010955 — intervention group
Intervention type: DRUG
Intervention: Edoxaban Monotherapy
Description: when the patients will be initially registered in this study, duty physicians will make a decision to give additional antiplatelet therapy in addition to standard edoxaban therapy.
Study NCT03335969 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: colon irrigation
Description: Study is to compare bowel movement patterns before and after colon irrigation.
Study NCT04501276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADG116
Description: For monotherapy ADG116 (Part A), ADG116 will be administered IV over 60 90 minutes until disease progression, intolerable toxicities, or withdrawal of consent, or up to 2 years.
Study NCT04501276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADG106
Description: For the ADG116-ADG106 combination regimen, ADG116 and ADG106 will be administered until disease progression, intolerable toxicities, or withdrawal of consent, or up to 2 years.
Study NCT04501276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti PD1 drug
Description: For the ADG116-anti PD1 combination regimen, ADG116 and anti PD1 will be administered until disease progression, intolerable toxicities, or withdrawal of consent, or up to 2 years.
Study NCT02470949 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Social Status
Description: The participants will be randomized to the Low Social Status Condition. On their second visit, they will undergo the condition in which they were not randomized to on their first visit.
Study NCT02470949 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Social Status
Description: The participants will be randomized to the High Social Status Condition. On their second visit, they will undergo the condition in which they were not randomized to on their first visit.
Study NCT00325013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic Acid (DHA)
Description: 800mg twice a day for 1 year
Study NCT01611467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-223
Description: 20 mg oral CC-223 capsule containing a microtracer of \[14C\]-CC-223 solution
Study NCT01611467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-223
Description: 20-mg oral CC-223 tablet under fasting or fed conditions
Study NCT04445064 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IO102
Description: 100µg each week during the 3 weeks prior to curative treatment (total of 3 to 4 doses maximum)
Study NCT04445064 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IO103
Description: 100µg each week during the 3 weeks prior to curative treatment (total of 3 to 4 doses maximum)
Study NCT02191163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antistax®
Study NCT02191163 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03689504 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home-based nutrition education
Description: Health promoters will use 24-hour dietary recall information to assess meal frequency and dietary diversity and then provide tailored nutrition coaching to parents.
Study NCT03689504 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based family gardening
Description: Health promoters will facilitate the building and maintenance of a family home garden using a square foot or container gardening method.
Study NCT03798912 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: RaniPill capsule containing octreotide
Description: Administration of a RaniPill capsule loaded with 100 mcg of octreotide. Serial blood samples will be collected over the following 4 h for pharmacokinetic analysis of octreotide a) injected intravenously and b) delivered directly into the jejunal wall by the RaniPill capsule.
Study NCT03798912 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: RaniPill capsule containing octreotide
Description: Administration of a RaniPill capsule loaded with 100 mcg of octreotide. Serial blood samples will be collected over the following 4 h for pharmacokinetic analysis of octreotide a) injected intravenously and b) delivered directly into the jejunal wall by the RaniPill capsule.
Study NCT02641366 — intervention group
Intervention type: DEVICE
Intervention: Electromagnetic tracking
Description: The electromagnetic tracking system will precisely measure the position of a patient's upper extremity in space during routine neurologic examination.
Study NCT02641366 — intervention group
Intervention type: PROCEDURE
Intervention: Tremor kinetics after DBS
Description: We will fit the patient with the electromagnetic sensors and then perform routine outpatient neurologic examinations with their DBS system in both the DBS on and the DBS off settings.
Study NCT02641366 — intervention group
Intervention type: PROCEDURE
Intervention: Tremor kinetics before and after DBS
Description: We will perform two testing sessions: the first session will be performed during a routine preoperative visit, the second session will be performed during a routine postoperative DBS programming visit in both the DBS on and the DBS off settings.
Study NCT04729920 — intervention group
Intervention type: DEVICE
Intervention: Mechanical insufflation/exsufflation device (MI-E)
Description: download of device (MI-E) data and self-reported satisfaction with the device
Study NCT01116219 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab, erlotinib
Description: * Bevacizumab 7.5 mg/kg i.v. every 3 weeks and~* Erlotinib 150 mg p.o. daily until progression.
Study NCT01116219 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab, pemetrexed, cisplatin
Description: Induction chemotherapy with~* Bevacizumab 7.5 mg/kg i.v. and~* Pemetrexed 500 mg/m2 i.v. and~* Cisplatin\* 75 mg/m2 i.v. every 3 weeks for a maximum of 4 cycles or until progression. Followed by maintenance therapy in patients without disease progression with~* Bevacizumab 7.5 mg/kg i.v. and~* Pemetrexed 500 mg/m2 i.v. every 3 weeks until progression.
Study NCT05209932 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online New Beginnings Program (eNBP)
Description: The eNBP is a five-hour, asynchronous, fully web-based adaptation of the group-based NBP that can be used on a smart phone, tablet or computer. Separate versions for fathers and mothers consist of the same didactic content and interactive exercises, with gender appropriate references, testimonials and video skills demonstrations.
Study NCT00259220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erythomycin
Description: erythomycin
Study NCT00259220 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: gastric lavage alone
Description: gastric lavage alone
Study NCT00259220 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: erythromycine and gastric lavage
Description: erythromycine and gastric lavage
Study NCT02408055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-8995
Study NCT02260908 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Enoxaparin 30 mg subcutaneously twice daily for six doses, starting 36-48 hours post-traumatic injury.
Study NCT02260908 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% normal saline in equal volume to active comparator given subcutaneously twice daily for six doses, starting 36-48 hours post-traumatic injury.
Study NCT00469755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adapalene Gel, 0.1%
Description: Apply once daily in the evening for 12 weeks
Study NCT00469755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tazarotene Cream, 0.1%
Description: Apply once daily in the evening for 12 weeks
Study NCT00469755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adapalene Gel, 0.1% + Tazarotene Cream, 0.1%
Description: Apply adapalene Gel, 0.1% once daily in the evening for 6 weeks and Tazarotene Cream, 0.1% once daily in the evening for 6 weeks
Study NCT00186056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Glucocorticoid antagonist
Study NCT00186056 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Inactive placebo tab
Study NCT03761043 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Professional Behavior Change Intervention
Description: IV to PO antimicrobial conversion guidelines for nurses, nurse in-services and internet education sessions, IV to PO antimicrobial conversion health record reminder, endorsement from antimicrobial stewardship program, prescribers, and nurse educators.
Study NCT00810719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib will be administered at 150 mg once daily by mouth on the following schedule: days 2-5, 9-12,16-26.
Study NCT00810719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: The dose for gemcitabine is 1,000 mg/m2 administered over 30 minutes as an intravenous infusion. The doses are administered weekly for 3 weeks (Days 1, 8 and 15) followed by one week of rest during which gemcitabine is not given. This 4 week period (28 days) constitutes a cycle.
Study NCT01015482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Remifentanil Infusion
Study NCT01015482 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Midazolam Infusion
Study NCT02119273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: See arm description
Study NCT02119273 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: See arm description
Study NCT01593540 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: metal-free interdental brush
Description: one time per day
Study NCT01593540 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: metal-core interdental brush
Description: one time per day
Study NCT00687076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: Daily dose of 10 mg of Ezetimibe
Study NCT00687076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niaspan
Description: Daily dose of 1500 mg of Niaspan
Study NCT00978809 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Epley maneuver
Study NCT00978809 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Semont maneuver
Study NCT02137590 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Spanish Black Radish product
Study NCT01809418 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: keePAP
Study NCT02033018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept Injection
Description: Aflibercept intravitreal injection
Study NCT02158754 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Corus CAD (ASGES)
Study NCT01842724 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Motec total wrist arthroplasty
Study NCT01842724 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remotion total wrist arthroplasty
Study NCT01738308 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Healing Touch
Description: When enter PACU + usual standard of care.~The Healing Touch practitioner will be at the bedside when the patient is first brought to the PACU. The HT practitioner will center and then attune with the child, connecting their energy with the child and setting the intention for healing for the child's highest good. The practitioner will then place one hand on the center of the patient's chest in the high heart area. The practitioner will hold this position until they feel a deep connection and quieting within the patient's energy. When the patient is awake and parents have been called to the bedside the HT practitioner will energetically ground and release the patient,